-transparent.png){kind=logo}
OBJECTIVE Although fluoropyrimidines, in particular, fluorouracil (5-FU) and fluorodeoxyuridine (FdUrd), are active alone and in combination with other agents in a variety of human malignancies, therapeutic selectivity, resistance, and efficacy have been a major limitation in cancer therapy. Preclinical and clinical results in advanced and adjuvant colorectal cancers confirmed that the therapeutic efficacy of fluoropyrimidines, with thymidylate synthase (TS) as a primary target, can be improved significantly with leucovorin (LV) modulation. With the recognition that TS is an important therapeutic target, direct and specific inhibitors have been developed and are under intensive preclinical and clinical evaluation, primarily in patients with colorectal cancer, with demonstrable activity. The direct TS inhibitors have been shown to be potent, with a high level of specificity under therapeutic conditions for TS. This includes ZD1694, AG337, and LY231514. To date, although the therapeutic activity of both direct and indirect inhibitors of TS is similar, differences in the magnitude and profile of toxicity have been observed. A phase III comparative evaluation of a direct inhibitor of TS (ZD1694) with an indirect inhibitor (5-FU/LV) has been completed and showed similar activity but reduced toxicity in favor of ZD1694. RESULTS Recognition that greater than 95% of the injected dose of 5-FU is rapidly inactivated by dihydropyrimidine dehydrogenase (DPD) to therapeutically inactive products, but with toxicity to normal tissues, led to the development of inhibitors of this enzyme with the aim to modify the therapeutic index of 5-FU. Several inhibitors in combination with 5-FU are under preclinical and clinical evaluation, including uracil and 5-chloro-2,4-dihydroxy pyridine, as modulators of 5-FU derived from its prodrug tegafur and 5-ethynyluracil as a modulator of 5-FU. CONCLUSIONS In this review, an update of the present status of direct and indirect inhibitors of TS is discussed, as well as the future prospect for new drugs alone and in combination.
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
December 2002,
Expert opinion on investigational drugs,
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
October 2000,
Seminars in oncology,
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
December 1999,
Seminars in oncology,
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
January 2005,
Cancer chemotherapy and biological response modifiers,
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
January 2003,
Cancer chemotherapy and biological response modifiers,
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
January 2002,
Cancer chemotherapy and biological response modifiers,
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
February 1996,
Clinical cancer research : an official journal of the American Association for Cancer Research,
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
January 2001,
Cancer chemotherapy and biological response modifiers,
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
January 1997,
Anti-cancer drugs,
Y M Rustum, and
A Harstrick, and
S Cao, and
U Vanhoefer, and
M B Yin, and
H Wilke, and
S Seeber
January 2018,
Vitamins and hormones,
